Potential Benefits of Expanded Palivizumab in American Indian Children Under the Age of 2 Years

Ryan M Close; Alvin S Palmer; James B McAuley

doi:10.1093/jpids/piad063

Potential Benefits of Expanded Palivizumab in American Indian Children Under the Age of 2 Years

J Pediatric Infect Dis Soc. 2023 Sep 27;12(9):522-524. doi: 10.1093/jpids/piad063.

Authors

Ryan M Close¹, Alvin S Palmer¹, James B McAuley¹

Affiliation

¹ Whiteriver Service Unit, Indian Health Service, Whiteriver, Arizona, USA.

PMID: 37671822
DOI: 10.1093/jpids/piad063

Abstract

Severe respiratory syncytial virus (RSV) infections disparately impact American Indian communities. We implemented a program that expanded palivizumab to all children under 2 years of age that led to significant reductions in RSV infections and hospitalizations for both high-risk and non-high-risk recipients in a rural American Indian community in Eastern Arizona.

Keywords: American Indian/Alaska Native; palivizumab; prophylaxis; respiratory syncytial virus; rural health.

© The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.